TNFAIP2 and acute myeloid leukemia: Recently, a somatic mutation in the 3′UTR of TNFAIP2, a known target of the PRAM1 oncogene, creates a new miRNA target site that results in a reduction of TNFAIP2 expression in a patient with acute myeloid leukemia [28].